COMP <GO>
KNSA vs JNJ // ALTMAN Z-SCORE & DEBT/EQUITY
Kiniksa Pharmaceuticals International plc Class A (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: KNSA 6
— JNJ 8
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: KNSA
LAST: $92.24 (-5.45%) • MKT CAP: $7.67B
balance-sheet
24.45
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
balance-sheet
5.59
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KNSA VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KNSA | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.50% | 67.90% | +20.60 | KNSA | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 25.50% | -15.60 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 18.5x | +76.50 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 1.78% | 2.97% | -1.19 | JNJ | /fcf-yield <GO> |
| Operating Margin | 11.40% | 34.70% | -23.30 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 8.70% | 28.50% | -19.80 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 60.10% | 6.00% | +54.10 | KNSA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 24.45 | 5.59 | +18.86 | KNSA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | KNSA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 7.20% | +0.10 | JNJ | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.0 | 60.4 | +2.63 | KNSA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.11 | 1.08 | +0.03 | KNSA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 109.1x | 23.0x | +86.10 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.67B | $662.49B | -$654.83B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KNSA REV | JNJ REV | KNSA GROSS % | JNJ GROSS % | KNSA FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $677.6M | $94.19B | 88.5% | 67.9% | $136.4M | $19.70B |
| FY 2024 | $423.2M | $88.82B | 85.6% | 69.1% | $25.4M | $19.84B |
| FY 2023 | $270.3M | $85.16B | 44.0% | 44.0% | $1.1M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KNSA // BETA 1.11
JNJ // BETA 1.08